Clinical Trial Landscape of PI3K Inhibitors in Breast Cancer Treatment
by Junjie Cao·Updated 2mo ago
11.1 KB1files
Available on 1 platform
Sign in to view source links and access this dataset
Description
A dataset of 87 clinical trials on PI3K inhibitors for breast cancer, compiled by Junjie Cao and last updated in April 2026. The data was extracted from eight major clinical trial databases up to January 1, 2026, using standardized search terms. It includes descriptive statistical analysis on trial phases, targets, agents, efficacy, safety, and publication status.
Use Cases
Analyzing geographic distribution of clinical research based on the described leadership of the United States and collaborative networks.
Evaluating publication bias and reporting rates based on the finding that over 60% of trials involving key targets remain unpublished.
Comparing efficacy and safety profiles of specific agents like alpelisib and inavolisib based on described progression-free and overall survival benefits.
Assessing the prevalence of specific adverse events like hyperglycemia and diarrhea based on the results summary.
Strengths
Data is derived from a systematic review of eight major clinical trial databases with a defined search cutoff date.
Includes 87 trials with inter-rater agreement assessed using Cohen’s kappa, suggesting a structured screening process.
Analysis includes specific, quantified findings such as Phase I trials accounting for 34.5% of studies and PI3Kα being the target in 46 trials.
Limitations
Row count and column-level documentation are absent; field semantics must be inferred after download.
The dataset is very small at 11.1 KB, indicating limited scope and likely summary-level data rather than individual patient records.
Provenance
Source
figshare, authored by Junjie Cao.
Collection Method
Systematic search of eight clinical trial databases using standardized MeSH/Emtree terms, with independent screening by two reviewers.
Time Range
Trials identified up to January 1, 2026.
Freshness
Last updated 2026-04-13 04:35:18; freshness should be verified.
Geography
Global, with specific mention of the United States, Europe, China, and Korea.